Pricing Log in Create free account

Q32 Bio Inc. (QTTB) vs SAB Biotherapeutics, Inc. (SABS)

Q32 Bio Inc. and SAB Biotherapeutics, Inc. are both Biotechnology companies. Q32 Bio Inc. and SAB Biotherapeutics, Inc. are of similar size ($267.5M and $263.5M). SAB Biotherapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Q32 Bio Inc. trades at 3.1×. SAB Biotherapeutics, Inc. grew revenue faster over the last twelve months: −60.3% against −307.3%. Across the 13 metrics below, Q32 Bio Inc. leads on 11 and SAB Biotherapeutics, Inc. on 2.

Valuation

Metric QTTB SABS Biotechnology median
P/E 3.07 n/m 10.60
P/S n/m 147.02 9.40
P/B 1.78 1.11 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales (13.63) 85.82 9.02
Earnings yield 32.54% (6.31%) (32.88%)
Free cash flow yield (6.84%) (24.01%) (23.13%)

Profitability

Metric QTTB SABS Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 72.14% (34.27%) (51.96%)
Return on assets 37.13% (28.97%) (46.06%)
Return on invested capital 0.00% (38.97%) 0.00%

Growth

Metric QTTB SABS Biotechnology median
Revenue growth (TTM) (307.33%) (60.26%) 6.76%
EPS growth (last fiscal year) 136.78% 78.53% 29.88%
Revenue growth, 5-year CAGR 100.32% — 9.75%
Net income growth, 5-year CAGR 0.00% (26.69%) 0.00%

Health

Metric QTTB SABS Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 20.30 9.22 4.97
Net debt to EBITDA (2.21) 2.03 1.01

Dividend

Metric QTTB SABS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric QTTB SABS Biotechnology median
Market cap 263.46m 267.50m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack